EMA Authorised: Kyntheum (brodalumab) — LEO Pharma A/S

View source ↗

Summary

EMA authorised Kyntheum (brodalumab) by LEO Pharma A/S for psoriasis; decision date 27 August 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Kyntheum (brodalumab)

Snippet

Status: Authorised. Therapeutic area: Psoriasis. MAH: LEO Pharma A/S. Decision date: 27/08/2025